Iain Peter Murray Buchanan
Director/Board Member at Allecra Therapeutics GmbH
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Aram Andrew Mangasarian | M | 54 |
Novexel SA
 Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France.
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 14 years |
| Bruce Sachs | M | 64 | 26 years | |
| Holger N. Reithinger | M | 58 |
Allecra Therapeutics GmbH
 Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | 11 years |
| Silvio Inderbitzin | M | 59 |
Aurealis Pharma AG
 Aurealis Pharma AG Miscellaneous Commercial ServicesCommercial Services Part of Aurealis Oy, Aurealis Pharma AG is a Swiss company that provides scientific research and development services. The company is based in Basel, Switzerland. The company was founded by Juha Matti Yrjänheikki.
Aurealis Oy
 Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | 8 years |
| Amanda Radford | F | 53 | 2 years | |
| Thomas Wirth | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | 14 years |
| Juha Matti Yrjänheikki | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | 11 years |
| Laurent Marc Andre Décory | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Helen Gearing | F | - | 3 years | |
| Antti Poso | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Markus Forsberg | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Igor Mierau | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Karen Bush | F | - |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | - |
| Tim Xiao | M | 37 |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | 8 years |
| Gareth Walters | M | - | 3 years | |
| Roger Meier | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Richard Francis | M | - | 3 years | |
| Lin Zheng Chen | M | - |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | - |
| Brooke Clarke | F | - | 3 years | |
| Felicity Gabbay | M | 72 | 2 years | |
| Richard Hennings | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Matthew Emmens | M | 72 | - | |
| Charlie Sanders | M | 91 | 14 years | |
| Ian Smith | M | 58 | 18 years | |
| Theodora Caroline Harold | F | 50 | 1 years | |
| Nicholas Benedict | M | - |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | 5 years |
| Stuart Shapiro | M | - |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | 4 years |
| Stuart J. M. Collinson | M | 64 | 9 years | |
| Elaine S. Ullian | F | 76 | 22 years | |
| Richard H. Aldrich | M | 69 | 12 years | |
| Thomas Auchincloss | M | 62 | 7 years | |
| Pravin Ramsewak Chaturvedi | M | 60 | 7 years | |
| Thierry Hercend | M | - | 4 years | |
| Kenneth Coleman | M | 75 |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | - |
| Engelbert Willink | M | 64 |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | - |
| Peter Spargo | M | - |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | - |
| Kerry K. Reinertsen | M | - | 5 years | |
| Eric Olson | M | 66 | 12 years | |
| Sean O'Brien | M | - | - | |
| Klaus K. Wilgenbus | M | 62 |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | - |
| Mark de Rosch | M | 61 | 9 years | |
| Michael Partridge | M | - | - | |
| Matthias Baumann | M | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 6 years |
| Mark Namchuk | M | - | 13 years | |
| Julie Krop | M | 57 | 14 years | |
| Donald Munoz | M | 56 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 2 years |
| Julius Knowles | M | 61 | 2 years | |
| Brian Tinmouth | M | 60 | 18 years | |
| Paul Hugh Anthony Clegg | M | 64 | 10 years | |
| Stephen H. Watkins | M | - | 2 years | |
| Frank Morich | M | 69 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 2 years |
| Michele Garufi | M | 70 |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | 3 years |
| William John Jenkins | M | 77 |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | - |
| Hector J. Gomez | M | 85 | 2 years | |
| Eve Elizabeth Slater | M | 78 | 3 years | |
| Sarah Cecil | F | 72 | 9 years | |
| Eric Brandt | M | 62 | 7 years | |
| Douglas Cole | M | 63 | - | |
| John Alam | M | 62 | 11 years | |
| Lynne Brum | F | 60 | 13 years | |
| Peter Mueller | M | 68 | 11 years | |
| Wei Li | M | 52 | 3 years | |
| N. Coles | M | 63 | 3 years | |
| Michael R. Slater | M | 77 |
Biogen SA
| 2 years |
| Johanna Messina-Power | F | 51 | 9 years | |
| Bart Henderson | M | 65 | 5 years | |
| Manuel A. Navia | M | 77 | 8 years | |
| Valerie Lynne Andrews | F | 64 | 12 years | |
| Jeremy Chadwick | M | 61 | 2 years | |
| Kenneth S. Boger | M | 77 | - | |
| François Thomas | M | 66 |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | 2 years |
| Sean P. Brusky | M | 47 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 37 | 51.39% |
| Germany | 13 | 18.06% |
| United Kingdom | 9 | 12.50% |
| Finland | 8 | 11.11% |
| France | 5 | 6.94% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Iain Peter Murray Buchanan
- Personal Network
